Seguir
Robert Haddad, M.D.
Robert Haddad, M.D.
Professor, Dana Farber Cancer Institute, Harvard Medical School, McGraw Chair Head and Neck Oncology
Dirección de correo verificada de dfci.harvard.edu
Título
Citado por
Citado por
Año
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ...
New England Journal of Medicine 375 (19), 1856-1867, 2016
48352016
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
MR Posner, DM Hershock, CR Blajman, E Mickiewicz, E Winquist, ...
New England Journal of Medicine 357 (17), 1705-1715, 2007
20992007
Recent advances in head and neck cancer
RI Haddad, DM Shin
New England Journal of Medicine 359 (11), 1143-1154, 2008
11532008
Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology
DG Pfister, S Spencer, D Adelstein, D Adkins, Y Anzai, DM Brizel, ...
Journal of the National Comprehensive Cancer Network 18 (7), 873-898, 2020
9072020
Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE …
LQM Chow, R Haddad, S Gupta, A Mahipal, R Mehra, M Tahara, R Berger, ...
Journal of Clinical Oncology 34 (32), 3838-3845, 2016
8762016
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck …
R Haddad, A O'Neill, G Rabinowits, R Tishler, F Khuri, D Adkins, J Clark, ...
The Lancet Oncology 14 (3), 257-264, 2013
7862013
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by …
RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ...
Oral oncology 81, 45-51, 2018
7692018
Head and neck cancers, version 2.2014
DG Pfister, S Spencer, DM Brizel, B Burtness, PM Busse, JJ Caudell, ...
Journal of the National Comprehensive Cancer Network 12 (10), 1454-1487, 2014
7332014
Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study
J Bauml, TY Seiwert, DG Pfister, F Worden, SV Liu, J Gilbert, NF Saba, ...
Journal of Clinical Oncology 35 (14), 1542-1549, 2017
6832017
NCCN guidelines insights: head and neck cancers, version 1.2018
AD Colevas, SS Yom, DG Pfister, S Spencer, D Adelstein, D Adkins, ...
Journal of the National Comprehensive Cancer Network 16 (5), 479-490, 2018
5782018
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial
MR Posner, JH Lorch, O Goloubeva, M Tan, LM Schumaker, NJ Sarlis, ...
Annals of oncology 22 (5), 1071-1077, 2011
5492011
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
D Miao, CA Margolis, NI Vokes, D Liu, A Taylor-Weiner, SM Wankowicz, ...
Nature genetics 50 (9), 1271-1281, 2018
5272018
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results …
JH Lorch, O Goloubeva, RI Haddad, K Cullen, N Sarlis, R Tishler, M Tan, ...
The lancet oncology 12 (2), 153-159, 2011
5132011
Head and neck cancer
MD Mody, JW Rocco, SS Yom, RI Haddad, NF Saba
The Lancet 398 (10318), 2289-2299, 2021
5082021
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum …
JPH Machiels, RI Haddad, J Fayette, LF Licitra, M Tahara, JB Vermorken, ...
The Lancet Oncology 16 (5), 583-594, 2015
470*2015
Characterization of HPV and host genome interactions in primary head and neck cancers
M Parfenov, CS Pedamallu, N Gehlenborg, SS Freeman, L Danilova, ...
Proceedings of the National Academy of Sciences 111 (43), 15544-15549, 2014
4312014
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
R Mehra, TY Seiwert, S Gupta, J Weiss, I Gluck, JP Eder, B Burtness, ...
British journal of cancer 119 (2), 153-159, 2018
4272018
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related …
KJ Harrington, RL Ferris, G Blumenschein, AD Colevas, J Fayette, ...
The Lancet Oncology 18 (8), 1104-1115, 2017
4222017
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised …
NY Lee, RL Ferris, A Psyrri, RI Haddad, M Tahara, J Bourhis, K Harrington, ...
The Lancet Oncology 22 (4), 450-462, 2021
4042021
Response and acquired resistance to everolimus in anaplastic thyroid cancer
N Wagle, BC Grabiner, EM Van Allen, A Amin-Mansour, A Taylor-Weiner, ...
New England Journal of Medicine 371 (15), 1426-1433, 2014
3652014
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20